CRC samples have shown an upregulation in expression levels of neoplastic MAPK1 and PARP1 mRNAs and downregulation in EP300 mRNA levels, whereas PLB-treated CRC cells showed results otherwise, with suppressed cell proliferation [112]. The gene discussed is PARP1; the disease is colorectal carcinoma.